New Diagnostics for Stroke and Heart Attack to Revolutionize Healthcare

Lund, Sweden – The SmiLe company Medqus Innovations is introducing a groundbreaking technology for the diagnosis of stroke and heart attack. The new technology analyzes the tissue content of constrictions in the carotid arteries, something that current methods in clinics are unable to do. It can therefore lead to better clinical decisions and save lives. The company has been accepted into the SmiLe incubator program. 

Medqus Innovations has developed advanced imaging analysis software for ultrasound examinations that distinguishes dangerous from harmless plaque in blood vessels. Annually, approximately 25,000 Swedes suffer a stroke, which, along with heart attacks, are the leading causes of illness and death globally. The company is a spin-off from research at Lund University and Region Skåne. 

Currently, clinical trials are underway in Malmö and Cambridge to evaluate the technology's effectiveness in identifying dangerous plaque and to see how well it monitors the results of drug treatments. The results from these studies will be available later this year and are expected to provide further insights to accelerate the technology's path to commercialization. 

"With our image analysis, doctors can assess patients more easily and take decision with novel and complementary important information. For instance, patients with smaller plaques are usually not operated today, but they can be as dangerous as larger ones depending on their composition – which we now can visualize. Our analysis is a significant step forward in optimizing healthcare, reducing the risk of unnecessary procedures and providing appropriate treatment to the right patient " says Tobias Erlöv, CEO and co-founder of Medqus Innovations. 

The company is now receiving support for its continued business development within the SmiLe incubator program, which offers a strategic platform and an extensive network that benefits the development of innovative companies. 

"Medqus Innovations has the potential to significantly impact how stroke and heart attack are diagnosed and treated. Their solution holds great promise for transforming healthcare by both improving patient outcomes and optimizing healthcare resources. We look forward to supporting Medqus on their journey toward commercialization and seeing them take the next step in revolutionizing healthcare," says Ulrika Ringdahl, Chief Operating Officer at SmiLe Venture Hub. 

For more information, please contact: Ulrika Ringdahl, COO at SmiLe, +46 (0)736-566232, ulrika.ringdahl@smileincubator.life 

or  

Tobias Erlöv, CEO of Medqus Innovations, tobias.erlov@bme.lth.se